66500-55-8

Basic information

• Product Name: 1,4-Dioxaspiro[4.5]decane-8-carboxylic acid
• Synonyms: 1,4-Dioxaspiro[4.5]decane-8-carboxylic acid;EOS-61698;cyclohexanone-4-carboxylic acid ethyleneacetal
• CAS NO: 66500-55-8
• Molecular Formula: C₉H₁₄O₄
• Molecular Weight: 186.20506
• Mol File: 66500-55-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1,4-Dioxaspiro[4.5]decane-8-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Dioxaspiro[4.5]decane-8-carboxylic acid(66500-55-8)
• EPA Substance Registry System: 1,4-Dioxaspiro[4.5]decane-8-carboxylic acid(66500-55-8)

Safety Data

• Hazardous Substances Data: 66500-55-8(Hazardous Substances Data)

Usage

General Description

1,4-Dioxaspiro[4.5]decane-8-carboxylic acid is a chemical compound characterized by a spiro functional group, which refers to compounds that have two molecular rings sharing a single atom. The chemical formula for this compound is C10H16O4, and it possesses a molecular weight of approximately 200.23 g/mol. In terms of physical properties, it is typically a solid at room temperature. Like many such compounds, it does not have well-recognized uses but is important in the field of organic chemistry for the study of molecular structure and reaction dynamics. 1,4-Dioxaspiro[4.5]decane-8-carboxylic acid is also incorporated into larger, more complex molecules in the development of drugs and is typically produced on a small scale for research purposes.

Upstream product

• 69947-09-7 1,4-dioxaspiro<4.5>decane-8-carbonitrile 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 107-21-1 ethylene glycol 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 874-61-3 4-oxocyclohexanecarboxylic acid 

Downstream Products

• 169822-51-9 8-(4'-tert-Butyl-4-hydroxy-bicyclohexyliden-4-yl)-1,4-dioxa-spiro[4.5]decane-8-carboxylic acid 

Relevant articles and documents

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Azabenzimidazole derivative having AMPK-activating activity

Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen, or substituted or unsubstituted alkyl, R1, R2 and R3 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl or the like, with the proviso that R1, R2 and R3 are not simultaneously hydrogen, X is a single bond, —S—, —O—, —NR5—, —C(═O)— or the like, R5 is hydrogen, or substituted or unsubstituted alkyl, Y is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl or the like.

FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS

The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.